David Kirn, M.D.

David Kirn, M.D.

President and Chief Executive Officerat4D Molecular Therapeutics· In proxies 2022–2025

Pay in FY2024-90% from the year before · 4D Molecular Therapeutics stock -72.5% the same year

David Kirn, M.D. was paid $1.0M in FY2024 (Dec), down 90%. 4D Molecular Therapeutics stock fell 72.5% that year.

Pay$100 in the stock at the end of FY21 → $25
Pay is from the Summary Compensation Table of each 4D Molecular Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. 4D Molecular TherapeuticsPublic company · 4 yr
    • President and Chief Executive Officer2022 – Present · 4 yrStock in role -41%
  2. Annual MeetingPublic company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Boards1

  • 4D Molecular TherapeuticsDirector · 10 yr on the boardNot independent—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?